GeoVax Labs
GOVX
12 hedge funds and large institutions have $1.13M invested in GeoVax Labs in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
42% more capital invested
Capital invested by funds: $798K → $1.13M (+$335K)
0.02% more ownership
Funds ownership: 0.02% → 0.03% (+0.02%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$759K |
| 2 |
Renaissance Technologies
New York
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$21.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.78K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.54K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$175 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$175 |
GOVX Hedge Fund Activity: Q4 2023 in Review
12 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in GeoVax Labs (GOVX) for Q4 2023, worth a combined $1.13M — up 42% from $798K a quarter earlier.
Fund positioning in GOVX was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $759K. The largest seller was Morgan Stanley, cutting an estimated $21.5K.
- 12 institutional investors held GeoVax Labs (GOVX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.13M of GeoVax Labs stock for Q4 2023, up 42% quarter-over-quarter.
- 2 funds opened new GeoVax Labs positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest GeoVax Labs buyer in Q4 2023 was Armistice Capital, an estimated $759K added.
- The largest GeoVax Labs seller in Q4 2023 was Morgan Stanley, an estimated $21.5K sold.
Based on aggregated 13F filings for Q4 2023.